Association of circulating levels of RANTES and -403G/A promoter polymorphism to acute heart failure after STEMI and to cardiogenic shock
Language English Country Italy Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Survival Analysis MeSH
- Biomarkers blood MeSH
- Chemokine CCL5 blood genetics MeSH
- Adult MeSH
- Myocardial Infarction blood genetics MeSH
- Polymorphism, Single Nucleotide * MeSH
- Shock, Cardiogenic blood genetics pathology MeSH
- Cohort Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Disease Progression MeSH
- Promoter Regions, Genetic * MeSH
- Aged MeSH
- Heart Failure genetics pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Biomarkers MeSH
- Chemokine CCL5 MeSH
Chemokines, including RANTES, play a crucial role in the processes of inflammation during cardiovascular disorders, including myocardial infarction, disease progression and complications. This study aimed to evaluate the role of RANTES -403G/A polymorphism and levels in circulation in processes of development and progression of myocardial infarction and cardiogenic shock. A total of 609 patients with ST-segment elevation myocardial infarction, 43 patients with cardiogenic shock and 130 control subjects were enrolled in the study. RANTES -403G/A promoter polymorphism and baseline serum RANTES levels were analyzed. In the present study, we associated RANTES -403G/A promoter polymorphism with acute heart failure in patients with myocardial infarction (p = 0.006) and ejection fraction 3 months after MI onset (p = 0.02). Further, a difference in circulating RANTES levels among controls and STEMI subjects, and a relation of serum levels with acute heart failure was observed (p = 0.03, p = 0.003, respectively). We found a significant difference when comparing cardiogenic shock patients and controls (p < 0.001), with the most significant difference between cardiogenic shock and AHF subgroup of STEMI patients (p < 0.001). We observed a decreasing tendency of serum RANTES levels with the severity of myocardial infarction and progression, with the lowest levels in patients with cardiogenic shock (cutoff level ≥80.4 ng/ml). Our results suggest the role of RANTES as a potential biomarker of cardiogenic shock and acute heart failure in the hospital phase after myocardial infarction.
See more in PubMed
Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1512-8 PubMed
PLoS One. 2012;7(10):e47211 PubMed
J Mol Cell Cardiol. 1997 Jan;29(1):419-23 PubMed
Cytokine. 1991 May;3(3):165-83 PubMed
Exp Clin Cardiol. 2012 Winter;17(4):205-9 PubMed
Circulation. 2004 May 11;109(18):2186-90 PubMed
Clin Exp Rheumatol. 2009 Jan-Feb;27(1 Suppl 52):S142-3 PubMed
Thromb Haemost. 2007 May;97(5):748-54 PubMed
Clin Sci (Lond). 2007 Oct;113(8):349-56 PubMed
Microcirculation. 2003 Jun;10(3-4):335-50 PubMed
J Interferon Cytokine Res. 2002 Feb;22(2):223-9 PubMed
Intensive Care Med. 2010 Apr;36(4):630-7 PubMed
Circulation. 2007 Oct 16;116(16):1812-20 PubMed
Eur Heart J. 2010 Oct;31(20):2501-55 PubMed
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):194-9 PubMed
Circulation. 2003 Feb 11;107(5):721-6 PubMed
Trends Immunol. 2001 Feb;22(2):83-7 PubMed
Genes Immun. 2000 Dec;1(8):509-14 PubMed
Immunol Rev. 2000 Oct;177:236-45 PubMed
Thromb Res. 2009 May;124(1):84-9 PubMed
Clin Chim Acta. 2011 May 12;412(11-12):1112-5 PubMed
Circulation. 2006 Oct 10;114(15):1599-607 PubMed
Eur Heart J. 2004 Aug;25(16):1438-46 PubMed
Molecules. 2013 Dec 11;18(12):15314-28 PubMed
J Immunol. 2000 Feb 1;164(3):1612-6 PubMed
Eur J Intern Med. 2007 Jul;18(4):288-94 PubMed
Mol Immunol. 2012 Oct;52(3-4):273-8 PubMed
Arterioscler Thromb Vasc Biol. 2007 Apr;27(4):929-35 PubMed
Eur Heart J. 2008 Dec;29(23):2909-45 PubMed
Diabetes Care. 2003 Mar;26(3):892-8 PubMed
BMC Cardiovasc Disord. 2012 Apr 25;12:31 PubMed
Atherosclerosis. 2001 Sep;158(1):233-9 PubMed
Circulation. 1998 Mar 31;97(12):1136-43 PubMed
Eur Heart J. 2011 Feb;32(4):459-68 PubMed
Mediators Inflamm. 2011;2011:525691 PubMed
Circulation. 2002 Dec 3;106(23):2961-6 PubMed
J Heart Lung Transplant. 1996 Dec;15(12):1194-9 PubMed
N Engl J Med. 2005 Apr 21;352(16):1685-95 PubMed
AIDS. 2000 Dec 1;14(17):2671-8 PubMed
Clin Chem. 2008 Jan;54(1):24-38 PubMed
Gene. 2011 Nov 1;487(1):103-6 PubMed
Eur J Immunogenet. 1999 Oct;26(5):375-6 PubMed
Br J Haematol. 2005 Feb;128(4):482-9 PubMed
Transplantation. 2001 Jun 15;71(11):1649-56 PubMed
Circulation. 2002 Sep 17;106(12):1523-9 PubMed
Circulation. 2001 Apr 3;103(13):1772-7 PubMed
J Antimicrob Chemother. 1998 Jan;41 Suppl A:1-7 PubMed
